AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03041285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idronoxil (NOX66) suppository
Description: Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~.
Study NCT03041285 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
Study NCT01357486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: patients receiving sorafenib 400 mg - twice a day
Study NCT01357486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: patients receiving pravastatin 40 mg - once a day
Study NCT01357486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib + Pravastatin
Description: patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
Study NCT01357486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patients receiving best supportive care
Description: palliative management
Study NCT01936545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol during liver transplantation.
Description: The anesthesia was maintained with propofol during liver transplantation.
Study NCT01936545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane during liver transplantation.
Description: The anesthesia was maintained with desflurane during liver transplantation.
Study NCT00003460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT00575809 — intervention group
Intervention type: OTHER
Intervention: Mucositis and nutritional assessments
Description: Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
Study NCT00209378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regional anticoagulation with citrate
Description: Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
Study NCT00209378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HfCitPre
Description: regional anticoagulation with citrate containing replacement solution
Study NCT00267748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate Continuous Daily Dosing
Description: Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
Study NCT00267748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate Schedule 4/2
Description: Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
Study NCT00381771 — intervention group
Intervention type: BEHAVIORAL
Intervention: Conservative management for xerostomia
Description: Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
Study NCT02213809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case method education in COPD
Description: In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
Study NCT02213809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional education in COPD
Description: Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
Study NCT03432078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapy
Description: Non-pharmacological treatment
Study NCT01784861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82
Study NCT01784861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02122237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly tDCS
Description: Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
Study NCT03648697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-TCR-T (YT-E001) cells
Description: EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment.
Study NCT02498626 — intervention group
Intervention type: OTHER
Intervention: venous saturations
Description: Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
Study NCT02630758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Yoga
Description: See study arm description.
Study NCT02630758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Control Condition
Description: See study arm description.
Study NCT01415427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110 - Weekly
Description: In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.~In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo.
Study NCT01415427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110 - Every Other Week
Description: In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.~In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo.
Study NCT04064775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart snacking intervention
Description: The smart snacking intervention aimed to examine whether peer-led nudging on social media influenced adolescents to reduce their self-reported ideal portion sizes for a variety of HED snacks and SSBs. In intervention 2, participants were randomly allocated to the intervention or control condition, and their ideal portion sizes were assessed through a survey at baseline and intervention end.
Study NCT03187665 — intervention group
Intervention type: DEVICE
Intervention: Radical 7
Description: The Radical 7 is the traditional wall-connected pulse oximeter currently used at Children's Hospital of Wisconsin (CHW) which requires a 12 foot cable connecting the patient to a wall unit. While being continuously monitored with the Radical 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
Study NCT03187665 — intervention group
Intervention type: DEVICE
Intervention: Radius 7
Description: The Radius 7 is a newer, partially wireless pulse oximeter which eliminates the cable connecting the patient to a wall unit by instead connecting to a small device worn on the patient's arm or leg. The small device then sends the continuous pulse oximeter data wirelessly to the central monitoring station. While being continuously monitored with the Radius 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
Study NCT03246737 — intervention group
Intervention type: OTHER
Intervention: monitoring
Study NCT02569762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose-Aspartame
Description: Sucralose or aspartame
Study NCT02569762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspartame-Sucralose
Description: Aspartame or sucralose
Study NCT01297270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: QD BI 201335
Study NCT01297270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Study NCT01297270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN/RBV
Study NCT01297270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: QD (once daily) BI 201335
Study NCT01297270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04049045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 mg
Description: Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
Study NCT04049045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
Study NCT04004884 — intervention group
Intervention type: DRUG
Intervention: Ulipristal Acetate
Description: Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
Study NCT03995615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: * After initial clinical evaluation, supra gingival calculus removal will be done. GCF samples will be collected from the control and test groups (Baseline samples) using paper strips (ORAFLOW). ® Group III patients will undergo a through oral hygiene instructions, full mouth supra-gingival and sub- gingival scaling and root planing clinical parameters will be re-recorded 6 weeks later and a 2nd GCF samples will be collected from selected test site from each patients following periodontal intervention.~* All the samples will be placed in eppendorf vials containing the buffer solution and samples will be stored at -800 c until the time of analysis by Enzyme -linked immune sorbent assay kit (ELISA) (GENX BIO) TM
Study NCT03249571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoid supplement
Description: 2-weeks ingestion of flavonoid supplement
Study NCT03249571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-week ingestion of placebo supplement
Study NCT03178227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photoaging Mirroring Intervention
Description: Medical students perform mirroring with the pupils in the schools where they shoot selfies with tablets and photoage them to future non-smokers vs. future smokers.
Study NCT00121212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carbon-11 acetate PET scan
Study NCT00121212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carbon-11 acetate PET scan
Study NCT01384578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxiphylline and Vitamin E
Description: Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
Study NCT01384578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Patients in control group will receive vitamin E 800 IU/day
Study NCT01612260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shensong Yangxin capsule
Description: ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
Study NCT01612260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Capsule
Description: 4 granules t.i.d. po for 12 weeks
Study NCT01052311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tredaptive (1 g extended release niacin+ 20 mg laropiprant)
Description: Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
Study NCT01052311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study NCT01052311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tredaptive
Description: Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
Study NCT02826109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PeriAcryl®90 HV
Study NCT04505228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safflower (Carthamus Tinctorius) IgG4 &#X7C; Serum &#X7C; Allergy
Description: The designed Chinese herb formulas
Study NCT04505228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate
Description: The basic treatment for heart disease
Study NCT04505228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate
Description: The basic treatment for heart disease
Study NCT00388908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders and opinion leader generated guidelines +/- leaflets and counselling
Study NCT00388908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT03064477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: Intervention group that carries out the Unified Protocol in a group format
Study NCT03064477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (TAU)
Description: TAU group that carries out Cognitive Behavioral Therapy in an individual format
Study NCT01112046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection
Description: Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives
Study NCT01112046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic resection
Description: Surgical treatment performed under general anesthesia
Study NCT02150590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Nocturnal nasal oxygen during stay at 2048 m
Study NCT02150590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Nocturnal nasal oxygen during stay at 2048 m
Study NCT02150590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sham oxygen (room air)
Study NCT02150590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham oxygen (room air)
Study NCT03875144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks
Study NCT03875144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
Study NCT03875144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
Study NCT03875144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
Study NCT03875144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
Study NCT00881777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency heating of the myocardial infarct scar
Description: Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
Study NCT00881777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG) surgery
Description: A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
Study NCT00881777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG) surgery
Description: A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
Study NCT03643874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halix albuterol 90 mcg
Description: albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg
Study NCT03643874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol HFA MDI 90 mcg
Description: albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
Study NCT02911532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue engineering conjunctiva transplantation
Description: During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
Study NCT03444285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm Up
Description: Run on a treadmill during 10 minutes without fatigue of the participant after this time.
Study NCT03444285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot Pack
Description: 20 minutes of hot-pack on both hamstring
Study NCT03721094 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immersive virtual reality
Description: In the IVR environment, four different 360-degrees videos were in sequence played as backdrop during the procedure. The videos reflected real life situations in the operating room with two videos representing calm periods, one video representing a light stressor and one video representing a severe stressor with a bleeding (2 ml/s) being triggered in the simulation. Participants complete the procedures while wearing the head mounted device.
Study NCT02863809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin, a water soluble vitamin, is an essential nutrient and a natural component of many foods.
Study NCT02863809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin, a water soluble vitamin, is an essential nutrient and a natural component of many foods.
Study NCT02863809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextran
Description: Dextran is used to increase the viscosity of the solution.
Study NCT02863809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextran
Description: Dextran is used to increase the viscosity of the solution.
Study NCT02863809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA Light Source
Description: Avedro's KXL® System is a UVA irradiation system that uses a light emitting diode (LED) to deliver a dose of UVA light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
Study NCT02555670 — intervention group
Intervention type: OTHER
Intervention: BIA
Description: Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
Study NCT02876887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa
Study NCT02876887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo